Supplementary Table 4. Adjusted HRs (95% CIs) of incident CVD, CHD and ACS according to groups of 5-year changes in differential leukocyte counts.
| Changes (×109/L) | CVD | CHD | ACS | |||
|---|---|---|---|---|---|---|
| Events/ Person-years | HR (95% CI) | Events/ Person-years | HR (95% CI) | Events/ Person-years | HR (95% CI) | |
| Neutrophil count change | ||||||
| Q1 (＜–0.65) | 648/12900 | 0.96 (0.86–1.06) | 539/13134 | 0.97 (0.86–1.08) | 213/11946 | 0.98 (0.82–1.18) |
| Q2–Q3 (–0.65 to 0.49) | 1349/26274 | 1.00 (ref ) | 1131/26789 | 1.00 (ref ) | 413/24074 | 1.00 (ref ) |
| Q4 (＞ 0.49) | 730/12561 | 1.10 (1.00–1.20) | 596/12884 | 1.06 (0.96–1.18) | 221/11497 | 1.08 (0.91–1.27) |
| Lymphocyte count change | ||||||
| Q1 (＜–0.56) | 788/13870 | 0.98 (0.89–1.09) | 662/14145 | 0.98 (0.88–1.09) | 276/12730 | 1.13 (0.95–1.34) |
| Q2–Q3 (–0.56 to 0.07) | 1275/24836 | 1.00 (ref ) | 1072/25320 | 1.00 (ref ) | 390/22819 | 1.00 (ref ) |
| Q4 (＞ 0.07) | 664/13073 | 0.99 (0.90–1.09) | 532/13387 | 0.93 (0.84–1.04) | 181/12015 | 0.88 (0.74–1.05) |
| Monocyte count change | ||||||
| Q1 (＜–0.26) | 317/5550 | 1.02 (0.88–1.17) | 263/5684 | 0.98 (0.84–1.15) | 118/5145 | 1.01 (0.80–1.27) |
| Q2–Q3 (–0.26 to 0) | 1142/22947 | 1.00 (ref ) | 975/23336 | 1.00 (ref ) | 393/21206 | 1.00 (ref ) |
| Q4 (＞ 0) | 332/5796 | 1.16 (1.03–1.32) | 273/5931 | 1.12 (0.98–1.28) | 96/5311 | 0.99 (0.79–1.24) |
| Eosinophil count change | ||||||
| Q1 (＜–0.08) | 216/4298 | 0.89 (0.75–1.05) | 184/4376 | 0.90 (0.75–1.08) | 72/3986 | 0.87 (0.65–1.16) |
| Q2–Q3 (–0.08 to 0.06) | 1358/26305 | 1.00 (ref ) | 1146/26806 | 1.00 (ref ) | 447/24264 | 1.00 (ref ) |
| Q4 (＞ 0.06) | 218/3676 | 1.03 (0.89–1.19) | 182/3757 | 1.03 (0.88–1.21) | 88/3394 | 1.26 (1.00–1.59) |
Abbreviation: CVD, cardiovascular disease; CHD, coronary heart disease; ACS, acute coronary syndrome; CI, confidence interval; HR, hazard ratio.
HRs were adjusted for age, sex, BMI, education, smoking status, drinking status, physical activity, hypertension, diabetes mellitus, hyperlipidemia, family history of CVD/CHD, intake of antibiotics or aspirin, and baseline differential leukocyte counts.